Detailed company information
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Aug 05, 2026
Earnings Transcript for 2026 - Q1Released: May 06, 2026
Earnings Transcript for 2025 - Q4Released: Feb 25, 2026
Earnings Transcript for 2025 - Q3Released: Nov 04, 2025
Earnings Transcript for 2025 - Q2Released: Aug 06, 2025
Earnings Transcript for 2025 - Q1Released: May 07, 2025
Earnings Transcript for 2024 - Q4Released: Feb 27, 2025
Earnings Transcript for 2024 - Q3Released: Nov 12, 2024
Earnings Transcript for 2024 - Q1Released: May 08, 2024
Earnings Transcript for 2023 - Q4Released: Feb 28, 2024
Earnings Transcript for 2023 - Q3Released: Nov 05, 2023
Earnings Transcript for 2023 - Q2Released: Aug 05, 2023
Earnings Transcript for 2023 - Q1Released: May 07, 2023
Earnings Transcript for 2022 - Q4Released: Mar 08, 2023
Earnings Transcript for 2022 - Q3Released: Nov 09, 2022
Earnings Transcript for 2022 - Q2Released: Aug 07, 2022
Earnings Transcript for 2022 - Q1Released: May 07, 2022
Earnings Transcript for 2021 - Q4Released: Mar 09, 2022
Earnings Transcript for 2021 - Q3Released: Nov 16, 2021
Earnings Transcript for 2021 - Q2Released: Aug 08, 2021
Earnings Transcript for 2021 - Q1Released: May 09, 2021
ARQT Arcutis Biotherapeutics, Inc.
AMLX Amylyx Pharmaceuticals, Inc.
BMRN BioMarin Pharmaceutical Inc.
LGND Ligand Pharmaceuticals Incorporated
VRDN Viridian Therapeutics, Inc.
LQDA Liquidia Corporation
MIR Mirion Technologies, Inc.
RARE Ultragenyx Pharmaceutical Inc.
ALNY Alnylam Pharmaceuticals, Inc.
XNCR Xencor, Inc.
TBPH Theravance Biopharma Inc
TVTX Travere Therapeutics, Inc.
Dafinchi